RU2017133649A3 - - Google Patents

Download PDF

Info

Publication number
RU2017133649A3
RU2017133649A3 RU2017133649A RU2017133649A RU2017133649A3 RU 2017133649 A3 RU2017133649 A3 RU 2017133649A3 RU 2017133649 A RU2017133649 A RU 2017133649A RU 2017133649 A RU2017133649 A RU 2017133649A RU 2017133649 A3 RU2017133649 A3 RU 2017133649A3
Authority
RU
Russia
Application number
RU2017133649A
Other languages
Russian (ru)
Other versions
RU2017133649A (ru
RU2729491C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017133649A publication Critical patent/RU2017133649A/ru
Publication of RU2017133649A3 publication Critical patent/RU2017133649A3/ru
Application granted granted Critical
Publication of RU2729491C2 publication Critical patent/RU2729491C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
RU2017133649A 2015-03-27 2016-03-23 Антитело, которое распознает пептид т14 асне RU2729491C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1505239.2A GB201505239D0 (en) 2015-03-27 2015-03-27 Antibody
GB1505239.2 2015-03-27
GB1600871.6 2016-01-18
GB1600871.6A GB2541477A (en) 2015-03-27 2016-01-18 Antibody
PCT/GB2016/050804 WO2016156803A1 (en) 2015-03-27 2016-03-23 Antibody that recognises the t14 peptide of ache

Publications (3)

Publication Number Publication Date
RU2017133649A RU2017133649A (ru) 2019-04-29
RU2017133649A3 true RU2017133649A3 (enExample) 2020-02-17
RU2729491C2 RU2729491C2 (ru) 2020-08-07

Family

ID=53178191

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017133649A RU2729491C2 (ru) 2015-03-27 2016-03-23 Антитело, которое распознает пептид т14 асне

Country Status (13)

Country Link
US (1) US10954306B2 (enExample)
EP (1) EP3274371B1 (enExample)
JP (1) JP7327897B2 (enExample)
KR (1) KR102626626B1 (enExample)
CN (1) CN107531796A (enExample)
AU (1) AU2016240020B2 (enExample)
BR (1) BR112017020769A2 (enExample)
CA (1) CA2979972A1 (enExample)
ES (1) ES2952723T3 (enExample)
GB (2) GB201505239D0 (enExample)
MX (1) MX392158B (enExample)
RU (1) RU2729491C2 (enExample)
WO (1) WO2016156803A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539161A (en) * 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
GB2546773B (en) * 2016-01-28 2020-06-17 Neuro Bio Ltd Cancer
GB201705044D0 (en) * 2017-03-29 2017-05-10 Neuro-Bio Ltd Biomarker
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
GB202112831D0 (en) * 2021-09-09 2021-10-27 Neuro Bio Ltd Biomarker
GB202113941D0 (en) 2021-09-29 2021-11-10 Neuro Bio Ltd Skin biomarker
EP4584388A1 (en) 2022-09-08 2025-07-16 Neuro-Bio Ltd Lateral flow device for diagnosing alzheimer's disease using the t14 peptide
GB202308799D0 (en) 2023-06-13 2023-07-26 Neuro Bio Ltd Neurodegenerative disease
GB202308779D0 (en) * 2023-06-13 2023-07-26 Neuro Bio Ltd Aptamer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606040D0 (en) * 1996-03-22 1996-05-22 Isis Innovation Active peptide
US20040038875A1 (en) 2000-03-29 2004-02-26 Greenfield Susan Adele Alpha 7nicotinic receptor screening assays
GB0028578D0 (en) * 2000-11-23 2001-01-10 Synaptica Ltd Screening assays
GB0502068D0 (en) * 2005-02-01 2005-03-09 King S College London Screening method
BRPI0615997A8 (pt) * 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
GB0708646D0 (en) * 2007-05-04 2007-06-13 Enkephala Ltd Biologically active C-terminal fragment of acetylcholinesterase
WO2009040789A2 (en) * 2007-09-24 2009-04-02 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
CN101530162B (zh) * 2008-03-10 2011-11-23 北京大北农科技集团股份有限公司 一种新型蛋白饲料添加剂的制备方法

Also Published As

Publication number Publication date
US20180051094A1 (en) 2018-02-22
US10954306B2 (en) 2021-03-23
WO2016156803A1 (en) 2016-10-06
GB2541477A (en) 2017-02-22
JP7327897B2 (ja) 2023-08-16
RU2017133649A (ru) 2019-04-29
MX392158B (es) 2025-03-21
CA2979972A1 (en) 2016-10-06
AU2016240020A1 (en) 2017-11-02
GB201505239D0 (en) 2015-05-13
KR20170138414A (ko) 2017-12-15
JP2018516849A (ja) 2018-06-28
RU2729491C2 (ru) 2020-08-07
MX2017012397A (es) 2018-01-26
ES2952723T3 (es) 2023-11-03
EP3274371B1 (en) 2023-06-07
CN107531796A (zh) 2018-01-02
AU2016240020B2 (en) 2022-02-17
KR102626626B1 (ko) 2024-01-17
GB201600871D0 (en) 2016-03-02
EP3274371A1 (en) 2018-01-31
BR112017020769A2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
BR112017027122A2 (enExample)
AU2022228198B1 (enExample)
CN303063546S (zh) 床扫(1)
CN303071169S (zh) 空气净化机
CN303071148S (zh) 除湿器
CN303070035S (zh) 智能记录仪配件(项链)
CN303065960S (zh) 斗碗
CN303067944S (zh) 料位器(角度可调的料位器)
BE2015C047I2 (enExample)
BE2015C044I2 (enExample)
BR0001536B1 (enExample)
BR0009182B1 (enExample)
BR0007834B1 (enExample)
BR0007487B1 (enExample)
BR0000695B1 (enExample)
BR0000126B1 (enExample)
BR0002874B1 (enExample)
BR0006634B1 (enExample)
BR0009649B1 (enExample)
BR0009373B1 (enExample)
BR0003686B1 (enExample)
BR0003208B1 (enExample)
BR0007468B1 (enExample)
BR0009994B1 (enExample)
BR0005041B1 (enExample)